Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company focused on developing immuno-oncology therapeutics. The company's pipeline centers on INTASYL compounds, a proprietary platform technology designed to modulate immune response in cancer treatment. The lead program, PH-762, targets PD-1 (programmed death protein 1) expression reduction and is advancing through Phase 1b dose-escalating clinical trials. A related program combines PH-762-treated double positive tumor infiltrating lymphocytes for Phase 1 evaluation in advanced melanoma and other solid tumors. A second clinical candidate, PH-894, aims to silence BRD4, a protein influencing gene expression in both T cells and tumor cells, and is currently in investigational new drug (IND) enabling studies.

The company operates as a preclinical and clinical development organization with no disclosed revenue streams, typical of early-stage biotechnology companies. With five full-time employees, Phio maintains a lean operational structure focused on drug development activities. The company is incorporated in Delaware and headquartered in Marlborough, Massachusetts. Phio Pharmaceuticals was formerly known as RXi Pharmaceuticals Corporation before its name change in November 2018.